Xenetic Biosciences, Inc. (XBIO)

Expanding the Potential of CAR T Cell Therapy

Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

Mar 29, 2021

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

Mar 17, 2021

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates